Corindus Vascular Robotics (NYSEAMERICAN:CVRS) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report released on Friday.

According to Zacks, “Corindus Vascular Robotics, Inc. is involved in designing, manufacturing and selling precision vascular robotic-assisted systems for interventional vascular procedures. The Company’s product includes CorPath 200 system a vascular robotic system which provide stent placement in percutaneous coronary intervention procedures. Corindus Vascular Robotics, Inc. is based in Waltham, Massachusetts. “

Other equities analysts also recently issued research reports about the company. ValuEngine downgraded Corindus Vascular Robotics from a “hold” rating to a “sell” rating in a report on Tuesday, October 3rd. BidaskClub downgraded Corindus Vascular Robotics from a “sell” rating to a “strong sell” rating in a report on Wednesday, October 11th. Two analysts have rated the stock with a sell rating, one has given a hold rating and two have assigned a buy rating to the company’s stock. Corindus Vascular Robotics has an average rating of “Hold” and a consensus target price of $2.33.

Shares of Corindus Vascular Robotics (NYSEAMERICAN:CVRS) traded down $0.02 on Friday, reaching $1.03. 212,712 shares of the company traded hands, compared to its average volume of 290,233. The company has a market capitalization of $198.14, a price-to-earnings ratio of -4.29 and a beta of 19.49. Corindus Vascular Robotics has a 52-week low of $0.40 and a 52-week high of $2.25.

Corindus Vascular Robotics (NYSEAMERICAN:CVRS) last issued its quarterly earnings data on Tuesday, November 7th. The medical equipment provider reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.05) by $0.01. The firm had revenue of $2.43 million for the quarter, compared to analyst estimates of $3.60 million. Corindus Vascular Robotics had a negative net margin of 323.84% and a negative return on equity of 110.93%.

A number of hedge funds have recently made changes to their positions in CVRS. Goldman Sachs Group Inc. grew its holdings in Corindus Vascular Robotics by 147.8% during the second quarter. Goldman Sachs Group Inc. now owns 58,824 shares of the medical equipment provider’s stock valued at $109,000 after purchasing an additional 35,086 shares during the last quarter. Rhumbline Advisers grew its holdings in Corindus Vascular Robotics by 67.6% during the second quarter. Rhumbline Advisers now owns 80,868 shares of the medical equipment provider’s stock valued at $150,000 after purchasing an additional 32,608 shares during the last quarter. New York State Common Retirement Fund grew its holdings in Corindus Vascular Robotics by 334.6% during the second quarter. New York State Common Retirement Fund now owns 89,100 shares of the medical equipment provider’s stock valued at $166,000 after purchasing an additional 68,599 shares during the last quarter. California State Teachers Retirement System grew its holdings in Corindus Vascular Robotics by 34.4% during the second quarter. California State Teachers Retirement System now owns 148,558 shares of the medical equipment provider’s stock valued at $276,000 after purchasing an additional 38,000 shares during the last quarter. Finally, Teachers Advisors LLC grew its holdings in Corindus Vascular Robotics by 184.7% during the second quarter. Teachers Advisors LLC now owns 167,633 shares of the medical equipment provider’s stock valued at $312,000 after purchasing an additional 108,745 shares during the last quarter.

ILLEGAL ACTIVITY WARNING: “Corindus Vascular Robotics (CVRS) Lowered to “Hold” at Zacks Investment Research” was originally published by American Banking News and is owned by of American Banking News. If you are accessing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright laws. The original version of this story can be read at https://www.americanbankingnews.com/2018/01/12/corindus-vascular-robotics-cvrs-lowered-to-hold-at-zacks-investment-research.html.

About Corindus Vascular Robotics

Corindus Vascular Robotics, Inc is engaged in robotic-assisted vascular interventions. The Company’s CorPath System is a medical device that brings robotic-assisted precision to radial, coronary and peripheral procedures. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries.

Get a free copy of the Zacks research report on Corindus Vascular Robotics (CVRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Corindus Vascular Robotics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corindus Vascular Robotics and related companies with MarketBeat.com's FREE daily email newsletter.